/
Oncology
Advanced Refractory Solid Tumors
8
Pipeline Programs↗
5
Active Trials↗
12
Companies Involved↗
Advanced Refractory Solid Tumors is an early-stage landscape with 8 programs across 12 companies.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Pipeline
Programs by Phase
Preclinical
No programs
Phase 26
Phase 3
No programs
Approved
No programs
Analysis
Modality Breakdown
71%
Small molecule
5 of 7 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 7 classified programs, each share of the total. Modality classified for 100% of 8 pipeline programs.
Analysis
Trial Status
25
clinical trials
Completed11 · 44%
Unknown status5 · 20%
Recruiting4 · 16%
Suspended2 · 8%
Withdrawn1 · 4%
Terminated1 · 4%
Other1 · 4%
Clinical Trials
Trial Activity
25 trials
Cetuximab β Combined With PRaG Regimen in the Treatment of EGFR-positive Advanced Refractory Solid Tumors
Not yet recruiting·SSecond Affiliated Hospital of Soochow University·Phase 2·NCT07327411·40 enrolled
Page 1 of 2
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)